Nguyen Dinh Van, Chu Hieu Chi, Nguyen Doan Van, Phan Minh Hong, Craig Timothy, Baumgart Karl, van Nunen Sheryl
Department of Allergy and Clinical Immunology, Hanoi Medical University, Hanoi 10000, Vietnam. ; Center of Allergology and Clinical Immunology, Bach Mai Hospital, Hanoi 844, Vietnam. ; Department of Allergy and Clinical Immunology, Royal North Shore Hospital and Sydney Medical School-Northern, The University of Sydney, Sydney, NSW 2065, Australia.
Center of Allergology and Clinical Immunology, Bach Mai Hospital, Hanoi 844, Vietnam.
Asia Pac Allergy. 2015 Apr;5(2):68-77. doi: 10.5415/apallergy.2015.5.2.68. Epub 2015 Apr 29.
In Vietnam, we observed a high incidence of carbamazepine (CBZ)-induced severe cutaneous adverse drug reactions (SCARs)-Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), and drug-induced hypersensitivity rash with eosinophilia and systemic symptoms (DRESS). In other Asian countries, HLA-B(*)1502 is an established risk factor for SCARs.
The aim of our study was to determine the frequency of HLA-B(*)1502 in SCARs patients at a large University Medical Center in Hanoi, Vietnam.
Thirty-eight cases of SCARs caused by CBZ and 25 patients with epilepsy tolerating CBZ were enrolled in a case-controlled study. Clinical manifestations and laboratory findings were recorded for each subject. Genomic DNA was isolated using the QIAamp DNA purification system. The combination of polymerase chain reaction and sequence specific oligonucleotide probes with the Luminex 100×MAP flow cytometry dual laser system was then used to quantitate fluorescently labelled oligonucleotides attached to colour-coded microbeads.
Cases comprised 20 SJS (52.6%), 7 TEN (18.4%), 8 overlap syndrome (21.1%), and 3 DRESS patients (7.9%). A strong association between HLA B(*)1502 and bullous skin reactions such as SJS/TEN and overlap was confirmed with an odds ratio (OR) of 33.78 (95% confidence interval [CI], 7.55-151.03), p < 0.0001, Sensitivity 91.4%, Specificity 76.0%, positive predictive value 84.2%, and negative predictive value 86.4%. We did not, however, observe any correlation between the presence of this allele and CBZ-induced nonbullous skin reactions (DRESS) (OR, 6.33; 95% CI, 0.48-82.74; p = 0.1592).
Our results indicate the presence of HLA-B(*)1502 in Vietnamese is a pharmacogenetic risk factor for developing CBZ-induced SJS/TEN.
在越南,我们观察到卡马西平(CBZ)引起的严重皮肤药物不良反应(SCARs)——史蒂文斯-约翰逊综合征(SJS)/中毒性表皮坏死松解症(TEN)以及药物性超敏反应伴嗜酸性粒细胞增多和全身症状(DRESS)的发生率很高。在其他亚洲国家,HLA - B(*)1502是SCARs的一个既定风险因素。
我们研究的目的是确定越南河内一家大型大学医学中心SCARs患者中HLA - B(*)1502的频率。
38例由CBZ引起的SCARs患者和25例耐受CBZ的癫痫患者纳入病例对照研究。记录每个受试者的临床表现和实验室检查结果。使用QIAamp DNA纯化系统分离基因组DNA。然后采用聚合酶链反应和序列特异性寡核苷酸探针与Luminex 100×MAP流式细胞术双激光系统相结合的方法,对附着在彩色编码微珠上的荧光标记寡核苷酸进行定量分析。
病例包括20例SJS(52.6%)、7例TEN(18.4%)、8例重叠综合征(21.1%)和3例DRESS患者(7.9%)。HLA B(*)1502与大疱性皮肤反应如SJS/TEN及重叠综合征之间存在强关联,优势比(OR)为33.78(95%置信区间[CI],7.55 - 151.03),p < 0.0001,敏感性91.4%,特异性76.0%,阳性预测值84.2%,阴性预测值86.4%。然而,我们未观察到该等位基因的存在与CBZ引起的非大疱性皮肤反应(DRESS)之间存在任何相关性(OR,6.33;95% CI,0.48 - 82.74;p = 0.1592)。
我们的结果表明,越南人HLA - B(*)1502的存在是发生CBZ诱导的SJS/TEN的药物遗传学风险因素。